利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.054 秒)

    Use of MDA-7 to inhibit pathogenic infectious organisms
    1.
    发明申请
    Use of MDA-7 to inhibit pathogenic infectious organisms 有权
    使用MDA-7抑制致病性感染性生物体

    公开(公告)号：US20050233959A1

    公开(公告)日：2005-10-20

    申请号：US11001702

    申请日：2004-12-01

    申请人： Sunil Chada

    发明人： Sunil Chada

    IPC分类号： A61K38/00 ,  A61K38/17 ,  A61K38/20 ,  A61K48/00 ,  C07K14/47 ,  C07K14/54

    CPC分类号： A61K38/20 ,  A61K9/0019 ,  A61K48/00 ,  C07K14/4748 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479

    摘要： Methods of suppressing or preventing an infection of a subject by a pathogen that involve administering to the subject a composition that includes a therapeutically effective amount of an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and a pharmaceutically acceptable preparation suitable for delivery to the subject, wherein the MDA-7 suppresses or prevents the infection, are disclosed. Also disclosed are methods of suppressing or preventing a viral infection of a cell, including obtaining an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and contacting the cell with the MDA-7 polypeptide or the nucleic acid encoding the MDA-7 polypeptide, wherein the MDA-7 suppresses or prevents infection of the cell.

    摘要翻译： 通过病原体抑制或预防受试者感染的方法涉及向受试者施用包含治疗有效量的MDA-7多肽或编码MDA-7多肽的核酸的组合物和适合的药学上可接受的制剂 用于递送到受试者，其中MDA-7抑制或预防感染。 还公开了抑制或预防细胞病毒感染的方法，包括获得MDA-7多肽或编码MDA-7多肽的核酸，并使细胞与MDA-7多肽或编码MDA的核酸接触 -7多肽，其中MDA-7抑制或预防细胞的感染。

    Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
    5.
    发明申请
    Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses 审中-公开
    用野生型自身基因转导的树突状细胞引起有效的抗肿瘤免疫应答

    公开(公告)号：US20050171045A1

    公开(公告)日：2005-08-04

    申请号：US11025796

    申请日：2004-12-29

    申请人： Dmitry Gabrilovich ,  David Carbone ,  Sunil Chada ,  Abner Mhashilkar

    发明人： Dmitry Gabrilovich ,  David Carbone ,  Sunil Chada ,  Abner Mhashilkar

    IPC分类号： A61K39/00 ,  A61K48/00 ,  C12N15/85 ,  C12Q1/68

    CPC分类号： C12N15/86 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/53 ,  A61K2039/54 ,  C12N2710/10343

    摘要： The present invention relates to immunotherapy methods for treating hyperproliferative disease or pathogen-induced diseases in humans. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is intradermally administered to said hyperproliferative cells. In another embodiment of the present invention, a pathogen-induced disease in which the pathogen gene expression is increaed or altered, is treated by intradermally administered a pathogen gene under the control of a promoter operable in eukaryotic cells. The present invention thus provides immunotherapies for treating hyperproliferative and pathogen diseases by attenuating the natural immune systems CTL response against hyperproliferative cells or overexpressing mutant p53 antigens.

    摘要翻译： 本发明涉及用于治疗人的过度增殖性疾病或病原体诱发的疾病的免疫治疗方法。 更具体地，在一个实施方案中，本发明涉及用过度增殖性疾病治疗受试者的方法，其中自身基因的表达在过度增殖细胞中上调。 在另一个实施方案中，包含在真核细胞中可操作的启动子控制下的自身基因的腺病毒表达构建体被皮内施用于所述过度增殖细胞。 在本发明的另一个实施方案中，病原体诱导的病原体基因表达增加或改变的疾病通过在可真核细胞中可操作的启动子的真皮内施用病原体基因进行治疗。 因此，本发明提供了通过减弱天然免疫系统CTL对抗过度增殖细胞或过表达突变型p53抗原来治疗过度增殖和病原体疾病的免疫疗法。

    Crossless retroviral vectors
    6.
    发明授权
    Crossless retroviral vectors 有权
    无反转录病毒载体

    公开(公告)号：US06333195B1

    公开(公告)日：2001-12-25

    申请号：US09479776

    申请日：2000-01-07

    申请人： James G. Respess ,  Nicholas J. DePolo ,  Sunil Chada ,  Sybille Sauter ,  Mordechai Bodner ,  David A. Driver

    发明人： James G. Respess ,  Nicholas J. DePolo ,  Sunil Chada ,  Sybille Sauter ,  Mordechai Bodner ,  David A. Driver

    IPC分类号： C12N15867

    CPC分类号： C12N15/86 ,  C12N2740/13043 ,  C12N2740/13052

    摘要： Retroviral vector constructs are described which have a 5′ LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand synthesis and a 3′ LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In addition, gag/pol, and env expression cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.

    摘要翻译： 描述了具有5'LTR，tRNA结合位点，包装信号，一个或多个异源序列，第二链合成起始和3'LTR的逆转录病毒载体构建体，其中载体构建体缺乏逆转录病毒gag / pol或env 编码序列。 此外，描述了gag / pol和env表达盒，其中表达盒缺少共同超过8个核苷酸的连续序列。 上述逆转录病毒载体构建体，gag / pol和env表达盒可用于构建排除形成复制能力的病毒的生产细胞系。

    Crossless retroviral vectors
    7.
    发明授权
    Crossless retroviral vectors 失效
    无反转录病毒载体

    公开(公告)号：US6013517A

    公开(公告)日：2000-01-11

    申请号：US850961

    申请日：1997-05-05

    申请人： James G. Respess ,  Nicholas J. DePolo ,  Sunil Chada ,  Sybille Sauter ,  Mordechai Bodner ,  David A. Driver

    发明人： James G. Respess ,  Nicholas J. DePolo ,  Sunil Chada ,  Sybille Sauter ,  Mordechai Bodner ,  David A. Driver

    IPC分类号： C12N15/48 ,  C12N15/867 ,  C12N5/10 ,  C12N15/86

    CPC分类号： C12N15/86 ,  C12N2740/13043 ,  C12N2740/13052

    摘要： Retroviral vector constructs are described which have a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand synthesis and a 3' LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In addition, gag/pol, and env expression-cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.

    摘要翻译： 描述了具有5'LTR，tRNA结合位点，包装信号，一个或多个异源序列，第二链合成起始和3'LTR的逆转录病毒载体构建体，其中该载体构建体缺乏逆转录病毒gag / pol或env 编码序列。 此外，描述了gag / pol和env表达盒，其中表达盒缺少多于8个核苷酸的连续序列。 上述逆转录病毒载体构建体，gag / pol和env表达盒可用于构建排除形成复制能力的病毒的生产细胞系。

    Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
    8.
    发明授权
    Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells 失效
    能够转染真核细胞的噬菌体介导的基因转移系统

    公开(公告)号：US5736388A

    公开(公告)日：1998-04-07

    申请号：US366522

    申请日：1994-12-30

    申请人： Sunil Chada ,  Thomas W. Dubensky, Jr.

    发明人： Sunil Chada ,  Thomas W. Dubensky, Jr.

    IPC分类号： A61K48/00 ,  C07K14/01 ,  C12N7/00 ,  C12N7/01 ,  C12N15/866 ,  C12N15/87 ,  C12N15/85 ,  C12N15/88

    CPC分类号： C12N15/86 ,  C07K14/005 ,  C12N15/87 ,  C12N7/00 ,  A61K48/00 ,  C12N2795/10322 ,  C12N2795/10343 ,  C12N2800/202

    摘要： Lamboid bacteriophage capable of specifically interacting with and delivering nucleic acid molecules to eukaryotic cells are disclosed. Such bacteriophage-derived gene transfer systems target one or more specific receptors on eukaryotic cells, for instance by incorporating mutant tail fiber proteins or by incorporating known ligands for specific eukaryotic receptors into lambda phage. Also disclosed are methods for identifying and producing modified bacteriophage tail fiber polypeptides capable of specifically interacting with eukaryotic transmembrane proteins. Methods of treating diseases using such gene transfer systems are also disclosed.

    摘要翻译： 公开了能够与真核细胞特异性相互作用并递送核酸分子的id噬噬菌体。 这样的噬菌体衍生的基因转移系统靶向真核细胞上的一种或多种特异性受体，例如通过掺入突变型尾纤维蛋白或通过将已知的特异性真核受体配体掺入λ噬菌体中。 还公开了用于鉴定和产生能够与真核跨膜蛋白特异性相互作用的修饰的噬菌体尾纤维多肽的方法。 还公开了使用这种基因转移系统治疗疾病的方法。